Sitagliptin use was not associated with an excess risk of all cause hospital admission or death compared with other glucose lowering agents among newly treated patients with type 2 diabetes (BMJ)
Diabetes News Service
Sitagliptin use was not associated with an excess risk of all cause hospital admission or death compared with other glucose lowering agents among newly treated patients with type 2 diabetes (BMJ)
For iPhone and iPad | For Android devices
For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com
Website by Wired up Wales